C - Chemistry – Metallurgy – 12 – N
Patent
C - Chemistry, Metallurgy
12
N
C12N 15/09 (2006.01) A61K 39/395 (2006.01) A61P 1/04 (2006.01) A61P 1/16 (2006.01) A61P 3/10 (2006.01) A61P 7/06 (2006.01) A61P 9/00 (2006.01) A61P 9/10 (2006.01) A61P 11/00 (2006.01) A61P 11/06 (2006.01) A61P 13/12 (2006.01) A61P 15/08 (2006.01) A61P 17/00 (2006.01) A61P 17/06 (2006.01) A61P 19/02 (2006.01) A61P 19/10 (2006.01) A61P 21/00 (2006.01) A61P 25/00 (2006.01) A61P 27/02 (2006.01) A61P 29/00 (2006.01) A61P 35/00 (2006.01) A61P 37/02 (2006.01) A61P 37/08 (2006.01) C07K 16/28 (2006.01) C12N 1/15 (20
Patent
CA 2699834
The amino acid sequences for a variable region and a constant region in TOCILIZUMAB, which is a humanized anti-IL-6 receptor IgG1 antibody, are modified so as to improve the pharmacokinetics of TOCILIZUMAB while enhancing the antigen-neutralizing ability of TOCILIZUMAB. In this manner, it becomes possible to produce a second-generation molecule which can be administered at reduced frequency, can exhibit its therapeutic effect sustainably, has improved immunogenicity, safeness and physical properties (stability and uniformity), and is therefore superior to TOCILIZUMAB. Thus, disclosed is a pharmaceutical composition comprising the molecule. Also disclosed is a method for producing the pharmaceutical composition.
Les séquences d'acides aminés d'une région variable et d'une région constante de TOCILIZUMAB, qui constitue un anticorps humanisé d'IgG1 anti-récepteur d'IL-6, sont modifiées afin d'améliorer les caractéristiques pharmacocinétiques du TOCILIZUMAB et de renforcer l'activité de neutralisation d'antigènes du TOCILIZUMAB. De cette manière, l'invention permet de produire une molécule de deuxième génération pouvant être administrée à une fréquence réduite, qui présente un effet thérapeutique durable et des propriétés d'immunogénicité, de sécurité et physiques améliorées (stabilité et uniformité), et est de ce fait supérieure au TOCILIZUMAB. L'invention concerne une composition pharmaceutique comprenant ladite molécule, et un procédé de production de cette composition pharmaceutique.
Higuchi Yoshinobu
Igawa Tomoyuki
Ishii Shinya
Kojima Tetsuo
Maeda Atsuhiko
Bereskin & Parr Llp/s.e.n.c.r.l.,s.r.l.
Chugai Seiyaku Kabushiki Kaisha
LandOfFree
Improved anti-il-6 receptor antibody does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Improved anti-il-6 receptor antibody, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Improved anti-il-6 receptor antibody will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1456938